The company said it plans to start clinical studies of CVT-301 by the end of 2011...
CVT-301 aims to give rapid, consistent and durable relief from debilitating motor fluctuations associated with Parkinson’s disease.

Civitas is developing a proprietary platform for inhaled therapeutics based on technology and underlying assets bought from Alkermes, including a large amount of intellectual property, a set of development stage pipeline candidates, specialized pulmonary equipment and a commercial-scale manufacturing plant.

Glenn Batchelder, CEO of Civitas, said the award from the foundation “provides important validation of our vision to improve Parkinson’s patients’ lives with an inhaled L-dopa therapeutic by overcoming the historical challenges in developing a better way to administer L-dopa.”

http://www.masshightech.com/stories/...Fox-grant.html